Triveni Bio is a technology company.
Triveni Bio has raised $212.0M across 2 funding rounds.
Triveni Bio has raised $212.0M in total across 2 funding rounds.
Triveni Bio has raised $212.0M in total across 2 funding rounds.
Triveni Bio's investors include Atlas Venture, Polaris Partners.
Triveni Bio is a clinical-stage biotechnology company developing genetics-informed precision antibody therapeutics for immunological and inflammatory (I&I) disorders, such as atopic dermatitis (AD), Crohn's disease, ulcerative colitis, psoriasis, and hereditary pancreatitis[1][2][3][5]. Its lead product, TRIV-509, is a dual-specific monoclonal antibody targeting kallikreins 5 and 7 (KLK5/7) to address barrier dysfunction, inflammation, and itch in moderate-to-severe AD, with a Phase 2 proof-of-concept trial underway after dosing the first patient in September 2025[3][6]. The company serves patients with unmet needs in I&I disorders where current treatments leave up to two-thirds inadequately managed, solving core disease pathologies through early proof-of-concept via genetic and mechanistic insights; it has raised $92M in Series A and $115M in Series B funding (total 10-100M+), fueling pipeline expansion including bispecific TRIV-573 (KLK5/7 + IL-13, clinic Q2 2026) and showing strong growth via recent IND plans, clinical initiations, and Fierce 15 recognition[1][3][5][6].
Founded in 2019 and headquartered in Waltham/Watertown, MA, Triveni Bio emerged from a vision to leverage genetics for precision medicine in I&I disorders, building on bold science to identify novel targets like KLK5/7[1][2][4]. Led by CEO Vishal Patel, Ph.D., the team includes experts like new CMO Bhaskar Srivastava, M.D., Ph.D., emphasizing a culture of collaboration, rigor, and patient impact; early traction came from preclinical superiority of TRIV-509 over IL-4R inhibitors in AD models and patient explants[3][4][5][6]. Pivotal moments include rapid Series A ($92M) and B ($115M) financings within a year, IND submission for TRIV-509 in Q1 2025, and Phase 2 initiation, marking its evolution from R&D to clinical momentum[1][5][6].
Triveni Bio rides the precision medicine and I&I therapeutics wave, targeting gaps in AD and related disorders where biologics like IL-4R/IL-13 inhibitors fail ~66% of patients by overlooking barrier dysfunction[3][6]. Timing aligns with rising AD prevalence, genetic sequencing advances, and bispecific antibody momentum, amplified by post-2020 biotech funding for inflammation targets[5]. Market forces favor it via validated KLK5/7 overexpression in barrier diseases and no approved hereditary pancreatitis therapies (affecting ~10K US patients); Triveni influences the ecosystem by pioneering genetics-driven antibodies, earning Fierce 15 2025 status, and expanding platforms for dermatology precision[3][5][6].
Triveni Bio's clinical-stage pipeline, headlined by TRIV-509 Phase 2 data and TRIV-573 IND in 2026, positions it to redefine AD standards and broaden into I&I combos[3][6]. Trends like AI-enhanced genetics, bispecifics, and personalized dermatology will accelerate its trajectory, potentially yielding first approvals amid $200M+ funding runway[5]. Its influence may grow via ecosystem partnerships and pipeline wins, evolving from precision pioneer to I&I leader—bringing hope through biology as envisioned.
Triveni Bio has raised $212.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $120.0M Series B | Atlas Venture, Polaris Partners | |
| Oct 1, 2023 | $92.0M Series A | Atlas Venture, Polaris Partners |